Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 3/20 | 0.40 |
| ▸ | BUB1 | O43683 | 2/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 2/20 | 0.32 |
| ▸ | PLK4 | O00444 | 1/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.32 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21678340 | 0.77 | CDC7 (0.36) | CDC7BUB1CRBNCDK9PLK4 | |
| SCHEMBL29738463 | 0.77 | CDC7 (0.43) | CDC7BUB1CRBNCDK9PLK4 | |
| SCHEMBL30625735 | 0.65 | CDC7 (0.40) | CDC7BUB1CRBNCDK9PLK4 | |
| SCHEMBL15690360 | 0.61 | CDC7 (0.53) | CDC7CDK9PLK4MAPK13DAPK3 | |
| SCHEMBL23340093 | 0.60 | SOS1 (0.47) | — | |
| SCHEMBL19154250 | 0.59 | LRRK2 (0.39) | CDC7LRRK2 | |
| SCHEMBL19152637 | 0.59 | PARP10 (0.38) | CDC7LRRK2 | |
| SCHEMBL17262729 | 0.59 | CDC7 (0.42) | CDC7CDK9PLK4MAPK13DAPK3 | |
| SCHEMBL19216379 | 0.58 | — | — | |
| SCHEMBL17234785 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002374-A1 | GPR52 MODULATOR COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-4055016-A1 | GPR52 MODULATOR COMPOUNDS | Heptares Therapeutics Limited (GB) | 2022-09-14 | — | — | EP | disclosed |
| CN-114650992-A | GPR52 modulator compounds | 赫普泰雅治疗有限公司 | 2022-06-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002374-A1 | GPR52 MODULATOR COMPOUNDS | GPR52, GPR119, GPR4 | CDC7 4082/4885BUB1 3770/4885CRBN 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.